```html

Yolk‑splenic Infarction in Sickle Cell Disease – A Complete Guide

Overview

Yolk‑splenic infarction (often called splenic infarction or “splenic sequestration”) is a painful, ischemic injury to the spleen that occurs when sickled red blood cells block the tiny vessels (the “yolk” of the spleen). In people with sickle‑cell disease (SCD) the spleen is one of the most frequently affected organs because its microcirculation is uniquely vulnerable to the rigid, crescent‑shaped cells that characterize the disease.

• Population affected: Almost all individuals with homozygous sickle‑cell anemia (HbSS) and a substantial proportion of those with HbSC or HbSβ‑thalassemia develop splenic complications.
• Age distribution: Acute infarction and sequestration are most common in children and adolescents (6 months – 25 years). After repeated infarctions, the spleen often becomes fibrotic and shrinks (autosplenectomy) in adulthood.
• Prevalence: Studies estimate that 30–40 % of children with HbSS experience at least one splenic sequestration episode, while chronic splenic infarction is present in up to 90 % of adults with SCD (Miller et al., *Blood* 2022; CDC 2023).

Symptoms

Symptoms can be abrupt (acute sequestration) or more subtle (chronic infarction). The presentation varies with age and severity.

• Sudden, severe left‑upper‑quadrant (LUQ) abdominal pain: Often described as “sharp” or “cramping.”
• Left‑sided rib or shoulder pain: Referred pain due to diaphragmatic irritation.
• Abdominal fullness or a palpable mass: The enlarged spleen may be felt 2–5 cm below the left costal margin.
• Rapid drop in hemoglobin/hematocrit: Can lead to pallor, fatigue, or dizziness.
• Acute anemia‑related symptoms: Shortness of breath, tachycardia, or syncope.
• Thrombocytopenia: Low platelet count may cause easy bruising or prolonged bleeding.
• Fever: May indicate concurrent infection or an inflammatory response.
• Jaundice: Resulting from hemolysis and hepatic congestion.
• Kidney dysfunction: Elevated creatinine if severe hypovolemia occurs.
• In chronic infarction: Recurrent mild pain, occasional left‑flank discomfort, and a progressively shrinking spleen on imaging.

Causes and Risk Factors

Sickle cell disease creates the perfect storm for splenic infarction.

• Polymerization of sickle hemoglobin (HbS): Deoxygenated HbS forms rigid polymers that distort red cells.
• Microvascular occlusion: Sickled cells obstruct the splenic sinusoids and trabecular arteries, causing ischemia.
• Dehydration and hypoxia: Both amplify sickling; common during infections, high altitude, or intense exercise.
• Infection: Respiratory or urinary infections increase metabolic demand and can trigger vaso‑occlusion.
• Blood transfusion without proper sickle‑cell matching: Can raise blood viscosity.
• Age: Young children have the most functional splenic tissue; older patients often have autosplenectomy, reducing acute risk but increasing susceptibility to encapsulated infections.
• Genotype: HbSS and HbSβ⁰ have higher risk than HbSC or HbSβ⁺.
• Co‑existing conditions: Thalassemia, G6PD deficiency, or other hemoglobinopathies increase vascular stress.

Diagnosis

Prompt recognition is essential because rapid splenic enlargement can lead to severe anemia and hypovolemic shock.

Clinical assessment

• History of SCD, recent illness, dehydration, or trauma.
• Physical exam: LUQ tenderness, palpable splenomegaly, signs of hypovolemia (tachycardia, hypotension).

Laboratory tests

• Complete blood count (CBC): Sudden drop in hemoglobin/hematocrit; thrombocytopenia.
• Reticulocyte count: Often elevated, reflecting bone‑marrow response.
• Lactate dehydrogenase (LDH) and indirect bilirubin: Markers of hemolysis.
• Serum electrolytes & creatinine: Assess volume status and renal function.
• Blood cultures: If fever is present.

Imaging

• Ultrasound (US): First‑line; shows an enlarged, heterogeneous spleen with absent Doppler flow in infarcted areas.
• Contrast‑enhanced CT scan: Gold standard for detailed assessment; reveals wedge‑shaped low‑attenuation areas and helps rule out rupture.
• MRI: Useful in children to avoid radiation; depicts infarcted tissue as areas of high signal on T2‑weighted images.

Additional studies

• Haplo‑type confirmation: Ensures accurate SCD classification (Hb electrophoresis, HPLC).
• Transcranial Doppler (TCD): Not diagnostic for splenic infarction but recommended annually in children with HbSS to gauge stroke risk, which can coexist.

Treatment Options

Management aims to (1) restore intravascular volume, (2) stop further sickling, and (3) prevent recurrence.

Acute care

1. Fluid resuscitation: Isotonic saline bolus 10–20 mL/kg; repeat as needed to maintain normotension.
2. Blood transfusion:
   • Simple transfusion to raise hemoglobin by 2–3 g/dL.
   • Exchange transfusion for severe anemia (Hb < 5 g/dL) or rapid splenic enlargement.
3. Oxygen therapy: 2–4 L/min via nasal cannula to reduce sickling.
4. Analgesia: Acetaminophen or NSAIDs (if renal function allows); consider short‑acting opioids for severe pain.
5. Empiric antibiotics: If fever or suspicion of infection (e.g., ceftriaxone).
6. Hydroxyurea optimization: Often started or dose‑adjusted during admission to increase fetal hemoglobin (HbF) and reduce future crises.

Procedural interventions

• Surgical splenectomy: Reserved for recurrent, life‑threatening sequestration or irreversible splenic necrosis. Laparoscopic approach is preferred when feasible.
• Partial splenectomy or embolization: Considered in adolescents where preserving some immune function is desirable.

Long‑term therapies

• Hydroxyurea: First‑line disease‑modifying agent; reduces vaso‑occlusive episodes by 30–50 % (NIH 2022).
• Chronic transfusion programs: Indicated for patients with ≥3 severe sequestration episodes per year.
• L‑glutamine (Endari®) or voxelotor (Oxbryta®): FDA‑approved agents that improve red‑cell flexibility and may lower crisis frequency.
• Vaccinations & prophylactic antibiotics: Essential after splenectomy or functional asplenia (pneumococcal, meningococcal, H. influenzae type b, annual flu shot).

Living with Yolk‑splenic Infarction (in sickle cell disease)

Self‑management empowers patients to reduce crisis frequency and detect problems early.

• Hydration: Aim for ≥ 2 L of fluid daily (more during hot weather or illness).
• Temperature control: Avoid extreme heat or cold; use fans/air‑conditioning and dress in layers.
• Regular medication adherence: Take hydroxyurea exactly as prescribed; set reminders.
• Routine follow‑up: Visit hematology clinic every 3–4 months; labs as ordered.
• Monitoring: Keep a log of pain, weight, and any “new” abdominal discomfort. Report a sudden drop in “normal” weight (>1 kg) as it may signal splenic pooling.
• Vaccination schedule: Follow CDC immunization guidelines for asplenic patients.
• Travel precautions: Carry an emergency card, a supply of oral rehydration salts, and a short‑acting pain kit.
• Psychosocial support: Join SCD support groups; consider counseling to cope with chronic illness stress.

Prevention

Because splenic infarction is a manifestation of the underlying sickle‑cell pathology, preventing vaso‑occlusion is the cornerstone.

• Hydroxyurea therapy: Initiate by age 9 months (per NHLBI recommendations) and continue lifelong unless contraindicated.
• Vaccination & prophylactic antibiotics: Penicillin prophylaxis until age 5 years (or longer if functional asplenia).
• Prompt treatment of infections: Early antibiotics reduce the inflammatory trigger for sickling.
• Maintain hydration and avoid dehydration: Especially during illness, travel, or intense physical activity.
• Reduce hypoxia: Use supplemental O₂ if altitude >2,500 m or during respiratory infections.
• Screen for and manage other risk factors: Control hypertension, avoid tobacco, and treat sleep apnea.
• Regular transfusion protocols: For high‑risk patients, maintain Hb > 9 g/dL with exchange transfusion to dilute HbS.

Complications

If not recognized promptly, yolk‑splenic infarction can lead to serious sequelae.

• Hypovolemic shock: Massive splenic pooling of blood can drop circulating volume.
• Acute chest syndrome: Common after splenic sequestration due to increased sickling burden.
• Sepsis: Functional asplenia predisposes to encapsulated bacterial infections.
• Chronic pain syndrome: Recurrent infarctions can cause neuropathic pain.
• Splenic rupture: Rare but life‑threatening; needs emergent surgery.
• Autosplenectomy: Progressive loss of splenic tissue leads to lifelong infection risk.
• Renal impairment: Secondary to hypoperfusion during severe sequestration.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC (Sickle Cell Disease Guidelines 2023), National Institutes of Health, World Health Organization, Cleveland Clinic, Miller et al., *Blood* 2022, NHLBI Recommendations for Sickle Cell Disease 2022.

```